Compare Amylx Pharmaceuticals Inc (AMLX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Jumia Technologies AG - ADR trades at $6.33 (market cap $719.58M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 3.7× Jumia Technologies AG - ADR's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| AMLX | JMIA | |
|---|---|---|
Market Cap | $2.64B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $14.60 |
52-Week Low | $7.82 | $5.69 |
Enterprise Value | $2.39B | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
JMIA trades at $6.245, up 4.08% on the day, amid a bearish technical signal and mixed fundamentals. The company reported revenue of $188.93M for 2025 with a gross profit margin of 54.75%, but net losses persist, and recent earnings have missed expectations. Analyst consensus is strongly bullish with 71.43% buy ratings, while technical indicators show selling pressure.
The outlook hinges on JMIA's path to profitability, targeting Q4 2026 breakeven and 2027 profitability. Risks include high cash burn and competitive pressures, but gross profit growth and strategic partnerships offer potential upside for patient investors focused on the African e-commerce market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
